Skip to main content
Clinical Trials/JPRN-UMIN000007070
JPRN-UMIN000007070
Completed
未知

The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis - CHALLENGE A plus trial

Department of Hepatology, Osaka City University Graduate School of Medicine0 sites50 target enrollmentMarch 31, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Hepatology, Osaka City University Graduate School of Medicine
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 31, 2015
End Date
June 30, 2014
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Hepatology, Osaka City University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The following patients were excluded 1\. women of childbearing potential and pregnancy, lactating women 2\. allergic to ribavirin or other nucleoside analoges 3\. an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) 4\. hemoglobibopathy ( thalassemia, sickle cell disease) 5\. severe renal disease or Ccr\<50mL/min 6\. severe depression or psychosomatic disorders 7\. severe liver diseases 8\. autoimmune hepatitis or HBV 9\. drug allegy against interferon 10\. allergic to vaccine or biological preperations 11\. concomitant herbal medication of Sho\-saiko\-to 13\. history of interstitial pneumonia 14\. patients who take active vitamin D3 other than Eldecalcitol 15\. other conditions considerd inappropriate by attending physician

Outcomes

Primary Outcomes

Not specified

Similar Trials